Market research
4QK.F Codexis, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 153M
- P/E ratio
- Not available
- Analyst target
- 29.5
- Dividend yield
- Not available
- Beta
- 2.5
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1920051067
- Market cap
- 153M
- P/E ratio
- Not available
- Analyst target
- 29.5
- Dividend yield
- Not available
- Beta
- 2.5
About
About Codexis, Inc
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4QK.F discussion.
5 years, 4 months ago
Codexis, Inc is currently in a long term uptrend where the price is trading 6.9% above its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.6.
Codexis, Inc's total revenue rose by 12.8% to $21M since the same quarter in the previous year.
Its net income has dropped by 517.3% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.9% to $-3M since the same quarter in the previous year.
Based on the above factors, Codexis, Inc gets an overall score of 4/5.